Boehringer In­gel­heim's Ofev wins FDA ap­proval for use in scle­ro­der­ma pa­tients

Five years af­ter se­cur­ing its first ap­proval in id­io­path­ic lung fi­bro­sis, Boehringer In­gel­heim’s drug Ofev has been cleared to slow the rate of pul­monary de­cline …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER